The revenue miss and guidance cut are concerning, but the strong profit growth and maintained profit/FCF guidance suggest cost controls are working. Watch the Q3 trading report on Nov 6 for signs of revenue acceleration in H2, particularly in US Orthopaedics and Advanced Wound Bioactives. The buyback provides a floor, but the stock may remain range-bound until revenue momentum improves.
Price Chart
Executive Summary
Smith & Nephew reported H1 2026 revenue of $3,097M (+2.3% underlying) and trading profit of $566M (+8.1%), beating profit expectations but missing revenue targets. Full-year revenue guidance was cut from ~6% to ~4%, though trading profit, free cash flow, and ROIC guidance were maintained. The $500M share buyback is underway ($216M settled) and the interim dividend was raised 4% to 15.6¢ per share.
Key Facts
- H1 2026 revenue $3,097M, underlying growth 2.3% (reported +4.6% incl. 230bps FX tailwind)
- Q2 2026 revenue $1,597M, underlying growth 1.6% (reported +2.8%)
- Trading profit $566M, up 8.1% reported; trading margin +60bps to 18.3%
- EPSA up 11.0% to 47.7¢; basic EPS up 6.2% to 35.6¢
- Full-year revenue guidance lowered from ~6% to ~4%; trading profit, FCF, ROIC guidance unchanged
- $500M share buyback announced May 2026, $216M settled as of Aug 3
- Interim dividend increased 4.0% to 15.6¢ per share
- Net debt $3,019M, adjusted leverage 1.8x; $4.7B committed facilities
Financial Impact
Revenue growth missed expectations by ~2pp (guidance cut from 6% to 4%), but trading profit grew 8.1% and margins expanded 60bps. The $500M buyback and 4% dividend increase provide shareholder return support.
Risk Factors
- US Orthopaedics weakness (Knee Implants -7.2%, Hip Implants -1.5% in Q2) may persist
- Advanced Wound Bioactives revenue declined -12.7% underlying in Q2 due to reimbursement changes
- Full-year revenue guidance cut implies H2 growth must accelerate to 5.0-5.5% — execution risk
- Skin substitutes headwind expected at upper end of $20-40M range
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-007206 |
| Document: 0001654954-26-007206-index-headers.html | 0001654954-26-007206 |
| Document: 0001654954-26-007206-index.html | 0001654954-26-007206 |
| Document: 0001654954-26-007206.txt | 0001654954-26-007206 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 16, 2026 16d ago | 6-K | $27.80 $26.82 | ▼ −3.53% | ▼ −6.09% | $26.42 (−4.96%) |
Sep 16, 2026 16d ago | 6-K | $27.80 $26.82 | ▼ −3.53% | ▼ −6.09% | $26.42 (−4.96%) |
Sep 11, 2026 21d ago | 6-K | $27.50 $27.56 | ▲ +0.22% | ▲ +0.44% | $26.42 (−3.93%) |
Sep 10, 2026 22d ago | 6-K | $27.62 $27.78 | ▲ +0.58% | ▲ +1.08% | $26.42 (−4.34%) |
Sep 10, 2026 22d ago | 6-K | $27.62 $27.78 | ▲ +0.58% | ▲ +1.08% | $26.42 (−4.34%) |
Sep 9, 2026 23d ago | 6-K | $27.80 $28.06 | ▲ +0.94% | ▲ +1.27% | $26.42 (−4.96%) |
Sep 8, 2026 24d ago | 424B5 | $27.87 $28.01 | ▲ +0.50% | ▲ +1.62% | $26.42 (−5.20%) |
Sep 2, 2026 4w ago | 6-K | $28.66 $27.62 | ▼ −3.63% | ▼ −2.67% | $26.42 (−7.82%) |
Sep 2, 2026 4w ago | 6-K | $28.66 $27.62 | ▼ −3.63% | ▼ −2.67% | $26.42 (−7.82%) |
Sep 1, 2026 4w ago | 6-K | $28.97 $27.80 | ▼ −4.04% | ▼ −4.12% | $26.42 (−8.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access